WuXi Biologics Placement: Pushing the Limits
Wuxi Biologics (Cayman) Inc (2269 HK) is a global one-stop biologics services provider and often referred to as CRO (contract research...
465 Views
Pharmaron Beijing: Trading Debut, Valuation Scenario Analysis
Pharmaron Beijing Co Ltd-H (3759 HK) is a global contract research organisation (CRO) and is one of the top three drug discovery service providers...
407 Views
HK Connect Flows: Close Meituan/Elong Trade with a 14.5% Profit
In our weekly HK Connect Flow series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed...
322 Views
Pharmaron Beijing IPO: H-Share Valuation Enticing
Pharmaron Beijing Co Ltd-H (3759 HK) is a global contract research organisation (CRO) and is one of the top three drug discovery service providers...
575 Views
Pharmaron Beijing IPO: Solid 9M19, but Is It Good Enough?
Pharmaron Beijing Co., Ltd. (A) (300759 CH) is a global contract research organisation (CRO) and is one of the top three drug discovery service...
403 Views